AMP, ASP, Best Price, AWP and WAC: Which Drug Price Moves Which Claim?

AMP, ASP, Best Price, AWP and WAC differ in whose price they describe and which government payment they affect. AMP and Best Price help set Medicaid rebates. ASP helps set Medicare Part B reimbursement. WAC is a manufacturer’s list price, while AWP is a published pricing benchmark. If you work in government pricing, contracting or finance, look beneath the reported number: which buyer counted, which discount disappeared and who decided to call a payment a service fee.

The direction matters. Improperly lowering AMP can leave state Medicaid programs with a smaller rebate. Improperly raising ASP can make Medicare pay more for a physician-administered drug. Both can benefit the manufacturer, through opposite treatments of a payment to a wholesaler or distributor.

AMP, ASP, Best Price, AWP and WAC Differences

These measures describe different parts of the sale. The comparison also needs NADAC, which measures retail pharmacy acquisition costs, and non-FAMP, which supplies the separate federal purchasing calculation.

WAC and AWP appear in pricing publications. NADAC and Medicare Part B payment limits are publicly posted. Manufacturer-specific AMP and Best Price submissions are confidential. A public payment benchmark does not show the decisions inside the manufacturer’s report.

Which Discounts Count Depends on the Program

AMP, ASP and Best Price each apply their own boundaries to the money moving between a manufacturer and its customers. A discount can belong in one calculation and be excluded from another.

AMP Follows the Retail Community Pharmacy Channel

Average Manufacturer Price begins with what wholesalers pay for drugs distributed to retail community pharmacies and what those pharmacies pay when buying directly. It excludes customary wholesaler prompt-pay discounts and bona fide service fees. Other financial transactions received by, paid by or passed through to retail community pharmacies can belong in the calculation.

The buyer classification matters. The ordinary AMP exclusions reach pharmacy benefit managers, hospitals, clinics, mail-order pharmacies and other buyers outside that retail channel. Special treatment applies to inhaled, infused, instilled, implanted and injected drugs that are not generally dispensed through retail community pharmacies. Applying the ordinary retail exclusion to those products can change which sales and concessions enter the average.

For most brand drugs, the basic Medicaid rebate is the greater of 23.1% of AMP or the difference between AMP and Best Price. Generic drugs use a basic rebate of 13% of AMP. An inflation component adds to both. The drug’s classification and base-period price help determine how much the manufacturer owes Medicaid.

Best Price Follows the Lowest Qualifying Deal

Best Price reaches wholesalers, retailers, providers, health maintenance organizations, nonprofits and government buyers, subject to exclusions. Cash discounts, rebates, purchase-dependent free goods and bundled discounts can affect that price. A bundle requires attention to the concessions across the products in the arrangement.

Prices under the Federal Supply Schedule and qualifying 340B sales are excluded. Prices negotiated by Medicare Part D plans are also excluded, while the negotiated maximum fair price for a selected drug is included in Best Price.

The 340B ceiling price generally uses AMP minus the Medicaid unit rebate amount. Understating the rebate can also leave safety-net health care providers paying more to acquire the drug.

ASP Follows Net Sales Across a Broader Market

Average Sales Price divides qualifying manufacturer sales by the units sold during the quarter. Its deductions include volume, prompt-pay and cash discounts, purchase-dependent free goods, chargebacks and specified rebates. Medicaid rebates are excluded, as are sales excluded from Best Price and sales at nominal charges.

This puts qualifying 340B and certain federal purchases outside ASP. A provider’s own discounted acquisition cost may therefore sit outside the average used to determine its reimbursement. The usual Medicare Part B payment formula is 106% of ASP, with exceptions and payment adjustments.

That makes the calendar part of the price. The July 2026 payment limits used first-quarter sales data, a two-quarter lag. The Centers for Medicare & Medicaid Services pricing files pair payment limits with a National Drug Code-to-billing-code crosswalk. We compare a transaction with the report and payment period it actually feeds.

Non-FAMP Belongs to Federal Purchasing

Non-FAMP supplies the Federal Ceiling Price calculation for federal drug purchases. The purchasers are the Department of Veterans Affairs, Department of Defense, Public Health Service and Coast Guard. The ceiling also incorporates an inflation adjustment.

A company can have Medicaid rebate obligations, 340B obligations and federal purchasing obligations for the same product. The federal ceiling uses its separate non-FAMP input. A pricing concern involving a VA purchase therefore needs the federal purchasing calculation and contract alongside any Medicaid report.

NADAC Measures a Different Side of the Transaction

NADAC looks at retail pharmacy purchase invoices. AMP looks at qualifying prices paid to the manufacturer. Those are different points in the distribution chain.

The Centers for Medicare & Medicaid Services methodology dated December 2024 describes a random sample of pharmacies asked to submit the previous month’s invoices voluntarily. Closed-door pharmacies that primarily supply drugs through the mail, including specialty pharmacies, are excluded.

A pharmacy’s reimbursement contract adds another layer. A maximum allowable cost list sets a reimbursement amount for a drug, and Medicaid payment rules also consider providers’ usual and customary charges to the public.

AWP Still Matters Where Payment Uses It

Average Wholesale Price can determine reimbursement even though it does not measure actual wholesale prices. Medi-Span’s pricing policy says its AWP depends on manufacturer reports and that it does not independently investigate whether those reports reflect transaction prices.

That distinction still matters in payment files. The agency’s July 2026 Part B file included vaccine and blood-product entries paid at 95% of AWP. Taxpayers can fund a payment based on a seller’s reported number that the publisher never checks against actual sales.

The AWP fraud pattern exploited the gap. The government alleged that companies reported high benchmarks, sold drugs at lower prices and marketed the resulting reimbursement spread to buyers. The buyer’s profit became a sales argument, financed by the payer using the published number.

McKesson’s 2012 settlement concerned allegations that it supplied inflated markup percentages to First DataBank, which published AWP benchmarks used by Medicaid. The alleged price manipulation happened in the information sent to the publisher. The reimbursement consequence happened downstream.

The Same Drug Basket Produces Different Prices

The Congressional Budget Office compared the measures for the same basket of 176 top-selling Medicare Part D brand-name drugs in 2017. Its February 2021 report used a standardized prescription of roughly 30 days.

Average AWP was $670 and WAC was $558. AMP averaged $509, while Best Price averaged $298.

The gap survives a common drug basket and a common prescription unit because the measures count different prices. Substituting WAC for AMP, or AWP for an invoice price, changes the question being answered.

List and net prices also have their own relationship. The Association Between Drug Rebates and List Prices, published by the USC Schaeffer Center in 2020, examined brand-drug list prices and estimated net prices. It found that increases in rebates were associated with increases in list prices.

The study’s rebate estimate included concessions across the distribution chain. It helps explain why a growing rebate can coexist with a rising list price. The statutory reporting question still turns on which particular concession belongs in AMP, ASP or Best Price.

How the Price Treatment Becomes a False Claim

These healthcare fraud cases connect a commercial decision to a reported number and then to government money. They also show why a service-fee label can have opposite effects in different programs.

AMP Reduced by Wholesaler Fees

Bristol-Myers Squibb agreed to a $75 million settlement in 2021 over allegations that it underreported AMP. The government described two treatments: improperly subtracting service fees paid to wholesalers and excluding additional value received through price-appreciation provisions in wholesaler contracts. The alleged result was smaller rebates to state Medicaid programs.

A whistleblower brought the case. The contract terms and the value exchanged supplied the connection between the company’s commercial arrangements and the government price report.

Best Price Missing the Hospital Bundle

Wyeth and Pfizer agreed to a $784.6 million settlement in 2016 over allegations that Wyeth hid bundled discounts on Protonix Oral and Protonix IV from Medicaid. The government alleged that the discounts encouraged hospitals to use the oral drug, which discharged patients were likely to keep taking while payers, including Medicaid, paid nearly full price.

The alleged hospital deal helped win the later prescription. According to the government, leaving that deal out of Best Price also deprived Medicaid of rebates. The commercial purpose and the reporting treatment were parts of the same arrangement.

ASP Raised by an Omitted Customer Benefit

Regeneron’s Eylea case presents the opposite fee treatment. In its April 2024 complaint announcement, the Justice Department alleged that Regeneron paid distributors’ credit-card processing fees for physician customers but failed to report those payments as ASP price concessions. It allegedly characterized the payments internally as bona fide service fees, leaving ASP and Medicare reimbursement inflated.

The whistleblowers’ complaint describes the alleged distributor-discount arrangement directly:

The alleged customer benefit stayed outside the manufacturer’s reported price because of how the companies described it. That is the connection an insider in contracting, distribution or government pricing may recognize.

The Records Behind the Reported Price

We work with you to connect the pricing workbook, contracts and payments to the report the company submitted, and to explain why a transaction entered or left the calculation.

Units deserve the same attention as dollars. Manufacturer ASP reporting identifies National Drug Codes, including package size, while Medicare payment uses billing codes. Several products can share a billing code. We connect the product and package to the payment unit before comparing the amounts.

Drug classification and the baseline can matter just as much. The Mylan EpiPen settlement addressed allegations that the company reported the product as a generic to avoid brand and inflation rebates. Mallinckrodt admitted that Acthar was not a new drug and agreed to correct its base-date AMP. A current price alone would miss both issues.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. The starting point for our review is the decision you can explain inside the business and the government payment it changed.

When You Know Why the Number Changed

If you know which discount was left out, which fee was reclassified or why a government price report changed, speak with our whistleblower experts about that decision. We work beside you to connect the transaction, the report and the government money, and bring in pharmaceutical pricing whistleblower lawyers who understand the calculation at issue. Your knowledge of how the business chose its numbers is where we begin building your case.